Reactive oxygen species explicit dosimetry to predict tumor growth for benzoporphyrin derivative-mediated vascular photodynamic therapy

Abstract. Photodynamic therapy (PDT) is a well-established treatment modality for cancer and other malignant diseases; however, quantities such as light fluence and PDT dose do not fully account for all of the dynamic interactions between the key components involved. In particular, fluence rate (ϕ) effects, which impact the photochemical oxygen consumption rate, are not accounted for. In this preclinical study, reacted reactive oxygen species ([ROS]rx) was investigated as a dosimetric quantity for PDT outcome. The ability of [ROS]rx to predict the cure index (CI) of tumor growth, CI  =  1  −  k  /  kctr, where k and kctr are the growth rate of tumor under PDT study and the control tumor without PDT, respectively, for benzoporphyrin derivative (BPD)-mediated PDT, was examined. Mice bearing radiation-induced fibrosarcoma (RIF) tumors were treated with different in-air fluences (Φ  =  22.5 to 166.7  J  /  cm2) and in-air fluence rates (ϕair  =  75 to 250   mW  /  cm2) with a BPD dose of 1  mg  /  kg and a drug-light interval (DLI) of 15 min. Treatment was delivered with a collimated laser beam of 1-cm-diameter at 690 nm. Explicit measurements of in-air light fluence rate, tissue oxygen concentration, and BPD concentration were used to calculate for [ROS]rx. Light fluence rate at 3-mm depth (ϕ3  mm), determined based on Monte-Carlo simulations, was used in the calculation of [ROS]rx at the base of tumor. CI was used as an endpoint for three dose metrics: light fluence, PDT dose, and [ROS]rx. PDT dose was defined as the product of the time-integral of photosensitizer concentration and ϕ3  mm. Preliminary studies show that [ROS]rx best correlates with CI and is an effective dosimetric quantity that can predict treatment outcome. The threshold dose for [ROS]rx for vascular BPD-mediated PDT using DLI of 15 min is determined to be 0.26 mM and is about 3.8 times smaller than the corresponding value for conventional BPD-mediated PDT using DLI of 3 h.

[1]  B. Pogue,et al.  Analysis of Effective Molecular Diffusion Rates for Verteporfin in Subcutaneous Versus Orthotopic Dunning Prostate Tumors¶ , 2004, Photochemistry and photobiology.

[2]  Timothy C Zhu,et al.  Parameter determination for singlet oxygen modeling of BPD-mediated PDT , 2013, Photonics West - Biomedical Optics.

[3]  Jarod C Finlay,et al.  Explicit dosimetry for photodynamic therapy: macroscopic singlet oxygen modeling , 2010, Journal of biophotonics.

[4]  Timothy C Zhu,et al.  Study of tissue oxygen supply rate in a macroscopic photodynamic therapy singlet oxygen model , 2015, Journal of biomedical optics.

[5]  Timothy C Zhu,et al.  Macroscopic singlet oxygen modeling for dosimetry of Photofrin-mediated photodynamic therapy: an in-vivo study , 2016, Journal of biomedical optics.

[6]  Timothy C Zhu,et al.  Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapy , 2009, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[7]  Xin-Hua Hu,et al.  Modeling of a Type II Photofrin-mediated Photodynamic Therapy Process in a Heterogeneous Tissue Phantom , 2005, Photochemistry and photobiology.

[8]  B. Pogue,et al.  Modeling PpIX effective light fluence at depths into the skin for PDT dose comparison. , 2019, Photodiagnosis and photodynamic therapy.

[9]  Timothy C Zhu,et al.  Explicit macroscopic singlet oxygen modeling for benzoporphyrin derivative monoacid ring A (BPD)-mediated photodynamic therapy. , 2016, Journal of photochemistry and photobiology. B, Biology.

[10]  Tayyaba Hasan,et al.  Tumor Vascular Permeabilization by Vascular-Targeting Photosensitization: Effects, Mechanism, and Therapeutic Implications , 2006, Clinical Cancer Research.

[11]  Michele M. Kim,et al.  Comparison of PDT parameters for RIF and H460 tumor models during HPPH-mediated PDT , 2014, Photonics West - Biomedical Optics.

[12]  Timothy C Zhu,et al.  Analytic function for predicting light fluence rate of circular fields on a semi-infinite turbid medium: erratum. , 2016, Optics express.

[13]  Jarod C Finlay,et al.  Comparison of singlet oxygen threshold dose for PDT , 2014, Photonics West - Biomedical Optics.

[14]  Jarod C Finlay,et al.  In-vivo singlet oxygen threshold doses for PDT , 2015, Photonics & lasers in medicine.

[15]  Timothy C Zhu,et al.  Evaluation of singlet oxygen explicit dosimetry for predicting treatment outcomes of benzoporphyrin derivative monoacid ring A-mediated photodynamic therapy , 2017, Journal of biomedical optics.

[16]  Timothy C Zhu,et al.  Evaluation of the 2‐(1‐Hexyloxyethyl)‐2‐devinyl pyropheophorbide (HPPH) mediated photodynamic therapy by macroscopic singlet oxygen modeling , 2016, Journal of biophotonics.

[17]  Michael R Hamblin,et al.  Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. , 2004, Photodiagnosis and photodynamic therapy.

[18]  Timothy C Zhu,et al.  In vivo outcome study of BPD-mediated PDT using a macroscopic singlet oxygen model , 2015, Photonics West - Biomedical Optics.

[19]  Timothy C Zhu,et al.  Parameter determination for BPD mediated vascularPDT , 2014, Photonics West - Biomedical Optics.

[20]  David Kessel,et al.  Photodynamic therapy of cancer: An update , 2011, CA: a cancer journal for clinicians.

[21]  Yi Hong Ong,et al.  Reactive oxygen species explicit dosimetry to predict local tumor control for Photofrin-mediated photodynamic therapy , 2019, BiOS.

[22]  N. Bressler,et al.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.

[23]  Yi Hong Ong,et al.  Singlet oxygen explicit dosimetry to predict long-term local tumor control for BPD-mediated photodynamic therapy , 2017, BiOS.

[24]  Michele M. Kim,et al.  Explicit dosimetry for 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a-mediated photodynamic therapy: macroscopic singlet oxygen modeling , 2015, Journal of biomedical optics.

[25]  Timothy C Zhu,et al.  Analytic function for predicting light fluence rate of circular fields on a semi-infinite turbid medium. , 2016, Optics express.

[26]  Timothy C Zhu,et al.  On the in vivo photochemical rate parameters for PDT reactive oxygen species modeling , 2017, Physics in medicine and biology.

[27]  Timothy C Zhu,et al.  Dosimetry study of PHOTOFRIN-mediated photodynamic therapy in a mouse tumor model , 2016, SPIE BiOS.

[28]  Jarod C Finlay,et al.  Macroscopic modeling of the singlet oxygen production during PDT , 2007, SPIE BiOS.